Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Dunn, 2004, The three Es of cancer immunoediting, Annu Rev Immunol, 22, 329, 10.1146/annurev.immunol.22.012703.104803

Dave, 2004, Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells, N Engl J Med, 351, 2159, 10.1056/NEJMoa041869

Wahlin, 2007, CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma, Clin Cancer Res, 13, 388, 10.1158/1078-0432.CCR-06-1734

Alvaro, 2006, Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients, J Clin Oncol, 24, 5350, 10.1200/JCO.2006.06.4766

Lee, 2008, A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones, J Immunol Methods, 331, 13, 10.1016/j.jim.2007.09.006

Yang, 2012, The tumor microenvironment in follicular lymphoma, Clin Adv Hematol Oncol, 10, 810

Kridel, 2012, Pathogenesis of follicular lymphoma, J Clin Invest, 122, 3424, 10.1172/JCI63186

Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, 26, 677, 10.1146/annurev.immunol.26.021607.090331

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239

Yang, 2006, Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma, Blood, 107, 3639, 10.1182/blood-2005-08-3376

Myklebust, 2013, High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells, Blood, 121, 1367, 10.1182/blood-2012-04-421826

Hardy, 2001, Treatment with BAT monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma, Int J Oncol, 19, 897

Hardy, 2005, BAT mAb induces lymphopoiesis in nude mice, Int Immunol, 17, 615, 10.1093/intimm/dxh244

Berger, 2008, Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies, Clin Cancer Res, 14, 3044, 10.1158/1078-0432.CCR-07-4079

Cheson, 2008, Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma, N Engl J Med, 359, 613, 10.1056/NEJMra0708875

Davis, 2000, Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment, J Clin Oncol, 18, 3135, 10.1200/JCO.2000.18.17.3135

Hainsworth, 2005, Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network, J Clin Oncol, 23, 1088, 10.1200/JCO.2005.12.191

Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403

Van Gelder, 1990, Amplified RNA synthesized from limited quantities of heterogeneous cDNA, Proc Natl Acad Sci USA, 87, 1663, 10.1073/pnas.87.5.1663

Ma, 2010, Effect of long-term storage in TRIzol on microarray-based gene expression profiling, Cancer Epidemiol Biomarkers Prev, 19, 2445, 10.1158/1055-9965.EPI-10-0565

Solal-Celigny, 2004, Follicular lymphoma international prognostic index, Blood, 104, 1258, 10.1182/blood-2003-12-4434

Federico, 2009, Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project, J Clin Oncol, 27, 4555, 10.1200/JCO.2008.21.3991

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690

Ame-Thomas, 2012, Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells, Leukemia, 26, 1053, 10.1038/leu.2011.301

Rawal, 2013, Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment, J Immunol, 190, 6681, 10.4049/jimmunol.1201363

Chang, 2013, Posttranscriptional control of T cell effector function by aerobic glycolysis, Cell, 153, 1239, 10.1016/j.cell.2013.05.016

Coiffier, 2011, Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial, Lancet Oncol, 12, 773, 10.1016/S1470-2045(11)70150-4

Armand, 2013, Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial, J Clin Oncol, 31, 4199, 10.1200/JCO.2012.48.3685

Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, 369, 134, 10.1056/NEJMoa1305133

Chung, 2011, Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions, Nat Med, 17, 983, 10.1038/nm.2426

Carreras, 2009, High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma, J Clin Oncol, 27, 1470, 10.1200/JCO.2008.18.0513

Wahlin, 2010, A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1—positive, regulatory, cytotoxic, and helper T cells and macrophages, Clin Cancer Res, 16, 637, 10.1158/1078-0432.CCR-09-2487

Richendollar, 2011, Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma, Hum Pathol, 42, 552, 10.1016/j.humpath.2010.08.015

Takahashi, 2013, Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era, Eur J Haematol, 90, 286, 10.1111/ejh.12075

Wherry, 2011, T cell exhaustion, Nat Immunol, 12, 492, 10.1038/ni.2035

Ansell, 2009, Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma, Clin Cancer Res, 15, 6446, 10.1158/1078-0432.CCR-09-1339

Yang, 2012, IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma, J Clin Invest, 122, 1271, 10.1172/JCI59806

O'Mahony, 2007, A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy, Clin Cancer Res, 13, 958, 10.1158/1078-0432.CCR-06-1974

Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/NEJMoa1302369

Schuster, 2011, Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma, J Clin Oncol, 29, 2787, 10.1200/JCO.2010.33.3005

Houot, 2009, T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy, Blood, 113, 3546, 10.1182/blood-2008-07-170274

Marabelle, 2013, Depleting tumor-specific Tregs at a single site eradicates disseminated tumors, J Clin Invest, 123, 2447, 10.1172/JCI64859

Houot, 2009, Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion, Blood, 114, 3431, 10.1182/blood-2009-05-223958